DekaBank Deutsche Girozentrale - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 123 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 3.73 and the average weighting 0.2%.

Quarter-by-quarter ownership
DekaBank Deutsche Girozentrale ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q4 2021$623,000
+66.6%
59,032
+15.2%
0.00%
+100.0%
Q3 2021$374,000
-50.8%
51,2500.0%0.00%
-50.0%
Q2 2021$760,000
-44.2%
51,250
-22.6%
0.00%
-60.0%
Q1 2021$1,362,000
+16.0%
66,2500.0%0.01%
+25.0%
Q4 2020$1,174,000
+128.0%
66,250
+91.8%
0.00%
+100.0%
Q3 2020$515,000
+181.4%
34,550
+287.6%
0.00%
+100.0%
Q2 2020$183,000
-9.9%
8,9140.0%0.00%
-50.0%
Q1 2020$203,000
+8.6%
8,914
-7.1%
0.00%
+100.0%
Q3 2019$187,000
-38.9%
9,600
-50.0%
0.00%
-50.0%
Q2 2019$306,000
-9.2%
19,200
+64.1%
0.00%0.0%
Q1 2019$337,000
+51.1%
11,700
+21.9%
0.00%
+100.0%
Q4 2018$223,000
-33.8%
9,600
-17.9%
0.00%
-50.0%
Q3 2018$337,000
+22.5%
11,700
-2.5%
0.00%0.0%
Q2 2018$275,000
-51.2%
12,000
-50.0%
0.00%
-50.0%
Q1 2018$563,000
-15.0%
24,000
-2.0%
0.00%
-20.0%
Q4 2017$662,0000.0%24,5000.0%0.01%0.0%
Q3 2017$662,000
-32.0%
24,5000.0%0.01%
-37.5%
Q2 2017$974,000
+9.4%
24,5000.0%0.01%0.0%
Q1 2017$890,000
+6.2%
24,500
-7.5%
0.01%
-11.1%
Q4 2016$838,000
-2.8%
26,500
+8.2%
0.01%
-10.0%
Q3 2016$862,000
+53.7%
24,5000.0%0.01%
+66.7%
Q2 2016$561,000
+87.0%
24,500
+50.3%
0.01%
+50.0%
Q1 2016$300,000
-5.4%
16,300
-15.1%
0.00%0.0%
Q4 2015$317,000
+69.5%
19,200
+12.9%
0.00%
+100.0%
Q3 2015$187,000
-8.3%
17,000
+8.3%
0.00%0.0%
Q2 2015$204,000
-22.1%
15,700
+4.0%
0.00%
-33.3%
Q1 2015$262,00015,1000.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Woodford Investment Management Ltd 10,898,879$264,297,00023.51%
Foundation Asset Management, LP 399,537$9,689,0003.59%
Cormorant Asset Management, LP 1,300,000$31,525,0002.35%
Baupost Group 9,309,168$225,747,0002.18%
Old West Investment Management, LLC 109,320$2,651,0001.53%
SENZAR ASSET MANAGEMENT, LLC 187,856$4,555,0001.44%
Chescapmanager LLC 350,631$8,503,0001.27%
Virtus ETF Advisers LLC 32,989$800,0000.69%
Rock Springs Capital Management LP 652,600$15,826,0000.68%
NJ State Employees Deferred Compensation Plan 34,142$828,0000.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders